Lespeol

Lespeol

SCHEMBL5522457

CC(C)=CCCC1(C)C=Cc2c(ccc(C(=O)/C=C/c3ccc(O)cc3)c2O)O1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 5/20 0.69
▸ ACHE P22303 2/20 0.69
▸ ODC1 P11926 2/20 0.69
▸ BCHE P06276 1/20 0.69
▸ BACE1 P56817 1/20 0.69
▸ DHODH Q02127 1/20 0.53
▸ MEN1 O00255 2/20 0.52
▸ LMNA P02545 2/20 0.52
▸ MAPT P10636 2/20 0.52
▸ MAOB P27338 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ HIF1AN Q9NWT6 1/20 0.51
▸ CTSK P43235 1/20 0.48
▸ SLC6A2 P23975 1/20 0.48
▸ HRH1 P35367 1/20 0.48
▸ OPRM1 P35372 1/20 0.48
▸ APP P05067 1/20 0.48
▸ PDE4D Q08499 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29435864 0.92 PTPN1 (0.58) PTPN1ACHEODC1BCHEBACE1
SCHEMBL5522452 0.90 PTPN1 (0.72) PTPN1ACHEODC1BCHEBACE1
SCHEMBL29775511 0.85 PTPN1 (0.51) PTPN1ACHEODC1BCHEBACE1
SCHEMBL30229516 0.83 PTPN1 (0.59) PTPN1ACHEBACE1MEN1MAPT
SCHEMBL23860681 0.83 PTPN1 (0.59) PTPN1ACHEBACE1MEN1MAPT
SCHEMBL31376263 0.82 PTPN1 (1.00) PTPN1ACHEODC1BCHEBACE1
SCHEMBL19960679 0.82 PTPN1 (1.00) PTPN1ACHEODC1BCHEBACE1
SCHEMBL16244637 0.82 ALOX5 (0.55) PTPN1ACHEODC1BCHEBACE1
SCHEMBL16244639 0.82 ALOX5 (0.55) PTPN1ACHEODC1BCHEBACE1
SCHEMBL31297038 0.82 XDH (0.57) PTPN1ACHEODC1BCHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 — — US claimed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 — — EP claimed
CN-119074703-A Application of chalcone compounds in preparation of anti-ischemic cerebral apoplexy drugs 暨南大学 2024-12-06 — — CN disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 — — US disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 — — US disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 — — US disclosed
CN-1816328-A Therapeutic agent TAKARA BIO INC (JP) 2006-08-09 — — CN disclosed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070092551-A1 Therapeutic agent FABP4, GPR119, IAPP PTPN1 1950/4885ACHE 3384/4885ODC1 3288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback